CORVUS PHARMACEUTICALS, INC. (NASDAQ:CRVS) Files An 8-K Submission of Matters to a Vote of Security HoldersItem 5.07Submission of Matters to a Vote of Security Holders.
On June 21, 2018 Corvus Pharmaceuticals,Inc. (the “Company”) held its 2018 Annual Meeting of Stockholders (the “Annual Meeting”) at 863 Mitten Road, Suite 102, Burlingame, California 94010. Only stockholders of record at the close of business on April 25, 2018, the record date for the Annual Meeting, were entitled to vote at the Annual Meeting. As of the record date, there were 29,193,690 shares of the Company’s common stock outstanding and entitled to vote at the Annual Meeting. At the Annual Meeting, 26,419,920 shares of the Company’s common stock were voted in person or by proxy for the two proposals set forth below, each of which is described in the Company’s Definitive Proxy Statement on Schedule 14A filed with the U.S. Securities and Exchange Commission on April 27, 2018.
The tabulation of the stockholder votes on each proposal brought before the Annual Meeting is as follows:
Proposal No.1 — Election of Directors
The Company’s stockholders elected the ClassI director nominees below to the Company’s Board of Directors to hold office until the 2021 Annual Meeting of Stockholders or until their respective successors are elected and qualified or appointed, or the earlier of their death, resignation or removal.
| ClassIDirectorNominees | VotesFor | VotesWithheld | BrokerNon–Votes |
| Steve E. Krognes | 20,020,111 | 5,226,255 | 1,173,554 |
| Scott W. Morrison | 24,862,897 | 383,469 | 1,173,554 |
Proposal No.2 — Ratification of Selection of Independent Registered Accounting Firm
The Company’s stockholders ratified the selection of PricewaterhouseCoopers LLC as the independent registered public accounting firm of the Company for its fiscal year ending December31, 2018.
| Votes For | Votes Against | Abstain |
| 24,455,773 | 5,603 | 1,958,544 |
About CORVUS PHARMACEUTICALS, INC. (NASDAQ:CRVS)
Corvus Pharmaceuticals, Inc. is a clinical-stage biopharmaceutical company. The Company is focused on the development and commercialization of immuno-oncology therapies. The Company is developing drugs and antibodies that block crucial immune checkpoints and reprogram immune T-cells. The Company has a pipeline of four immuno-oncology programs, three of which focus on the adenosine-cancer axis to modulate an immune response. The Company’s lead product candidate, CPI-444, is an oral, small molecule antagonist of the A2A receptor for adenosine, an immune checkpoint. Its other products include adenosine production inhibitor (a monoclonal anti-CD73 antibody); adenosine A2B antagonist, and interleukin-2 (IL-2)-inducible T cell kinase (ITK) inhibitors. As of September 30, 2016, the Company had not generated any revenue.